With funding from Bill Gates and others, the Diagnostics Accelerator aims to support the development of new biomarkers for the early detection of Alzheimer's.

The partners will develop an amyloid β 42/40 ratio assay to identify patients who may benefit from treatment with Janssen's drug called atabecestat.

In a study, the researchers used patients' blood plasma and infrared spectroscopy to diagnose dementias, and differentiate different forms of the condition from each other.